R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Respiratory syncytial virus (RSV) is one of the most common viral pathogens that cause acute respiratory infections in infants. In recent years, due to the persistently high incidence of various respiratory diseases, inhalation preparations have seen a growing market demand, especially when used in treating RSV-associated lower respiratory infections in children, thus aerosol inhalation has become a more ideal route of administration. Respiratory syncytial virus (RSV) is one of the most common...

Respiratory syncytial virus (RSV) is one of the most common viral pathogens that cause acute respiratory infections in infants. In recent years, due to the persistently high incidence of various respiratory diseases, inhalation preparations have seen a growing market demand, especially when used in treating RSV-associated lower respiratory infections in children, thus aerosol inhalation has become a more ideal route of administration.

However, due to various challenges such as specific requirements for the physicochemical and pharmacological properties of inhaled aerosol drugs, the uncertainty of therapeutic effects by depositing atomized drug particles in airways and lungs, as well as strict approval procedures for pediatric medication, inhaled protein therapeutics for children have yet to be marketed in China. Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.

View original content:https://www.prnewswire.co.uk/news-releases/rd-progress-enrollment-of-subjects-in-phase-iii-clinical-trial-for-inhaled-aerosol-drug-in-children-by-kexing-biopharm-302112540.html